- Show all
- Abigail Coursolle
- Alejandra Pavisich
- Alexis Robles-Fradet
- Alicia Emanuel
- Amy Chen
- Andy DiAntonio
- Brian Brooks
- Candace Gibson
- Carly Myers
- Cat Duffy
- Catherine McKee
- Cathren Cohen
- Charly Gilfoil
- Corey Davis
- Dania Douglas
- Daniel Young
- daryln
- David Machledt
- Elizabeth Edwards
- Elizabeth G. Taylor
- Eskedar Girmash
- Fabiola Carrión
- Georgesula Ziama
- Geron Gadd
- Hannah Eichner
- Hayley Penan
- Héctor Hernández-Delgado
- Ian McDonald
- Jane Perkins
- Jasmine Young
- Jennifer Lav
- Joe McLean
- Kasey Nichols
- Kimberly Lewis
- Leonardo Cuello
- lhigashi
- Lisa Munoz
- Liz McCaman Taylor
- Madeline Morcelle
- Mara Youdelman
- Maya Levin
- Michelle Lilienfeld
- Michelle Yiu
- Miriam Delaney Heard
- Mizue Suito
- Priscilla Huang
- Rachel Holtzman
- Sarah Grusin
- Sarah Somers
- Skyler Rosellini
- Susan Berke Fogel
- T. Nancy Lam
- veng
- Wayne Turner
- Zamir M. Brown
- Show all
- Alabama
- Alaska
- All United States
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- National
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- December 18, 2018
Amicus Brief in Support of Maryland’s Anti-Price Gouging Law for Prescription Drugs
Read moreThe National Health Law Program filed an amicus brief with the United States Supreme Court asking it to review a 4th Circuit decision that struck down Maryland's anti-price gouging law for prescription drugs as unconstitutional. The brief focuses on the impact of high drug costs on low-income people and…
- December 14, 2018
Comments to the FDA Urging Approval of Over the Counter Naloxone
Read moreThe National Health Law Program strongly urges the Food and Drug Administration (FDA) to initiate the process of moving at least one naloxone product from prescription to over the counter (OTC) status. Naloxone, a safe and effective medication, reverses opioid overdose if given in time, but is often not…
- December 1, 2016
Fact Sheet: Utilization Controls for Medicaid Prescription Drugs
Abbi Coursolle Manual/ReportRead moreState Medicaid programs that elect to provide outpatient prescription drug coverage must cover all FDA-approved drugs that are offered by a manufacturer that agrees to provide rebates. Nevertheless, states have substantial discretion to use utilization control techniques to steer Medicaid beneficiaries toward or away from certain drugs, within limits.…
- November 30, 2016
Fact Sheet: Medicaid Outpatient Prescription Drugs
Read morePrescription drug coverage is an important facet of the Medicaid program. Although an optional benefit, all states cover outpatient prescription drugs in their Medicaid programs.This fact sheet provides an overview of Medicaid outpatient prescription drug coverage, including: federal minimum requirements, state restrictions on prescription drug access, and special rules…
- April 26, 2016
Covered California: 2016 Benefit Designs: Cost Sharing for Prescription Drugs & Tiered Network Designs
Abbi Coursolle and Kim Lewis LetterRead moreRecommendations concerning the changes the California Covered Board will contemplate at its Board meeting this month regarding the 2016 standard benefit designs.
- March 7, 2016
NHeLP Comments to the Senate Finance Committee on the High Price of Prescription
Read moreNHeLP letter to the Senate Finance Committee in response to the request for public comment on policy issues including the financial impact of high prices of breakthrough drugs, data on prescription drug costs, and ensuring patient access, particularly for low income and vulnerable populations. Commments follow after an 18 month investigation…